Patents by Inventor Colin O'Dowd

Colin O'Dowd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)
    Patent number: 11807646
    Abstract: Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 7, 2023
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: James Samuel Shane Rountree, Steven Kristopher Whitehead, Adam Piotr Treder, Lauren Emma Proctor, Steven David Shepherd, Frank Burkamp, Joana Rita Castro Costa, Colin O'Dowd, Timothy Harrison
  • PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
    Publication number: 20220194947
    Abstract: The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 23, 2022
    Inventors: Peter HEWITT, Frank BURKAMP, Andrew WILKINSON, Hugues MIEL, Colin O'DOWD
  • PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
    Publication number: 20220033397
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those a compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: February 3, 2022
    Inventors: James Samuel Shane ROUNTREE, Steven Kristopher WHITEHEAD, Adam Piotr TREDER, Lauren Emma PROCTOR, Steven David SHEPHERD, Frank BURKAMP, Joana Rita Castro COSTA, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYCKA, Aaron CRANSTON, Xavier JACQ
  • USP19 INHIBITORS FOR USE IN THERAPY
    Publication number: 20220016115
    Abstract: Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: James Samuel Shane ROUNTREE, Peter HEWITT, Mary Melissa MCFARLAND, Frank BURKAMP, Christina BELL, Colin O'DOWD, Timothy HARRISON, Matthew Duncan HELM, Ewelina ROZYKA, Aaron CRANSTON, Xavier JACQ, Lauren PROCTOR
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20220002264
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 6, 2022
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
    Patent number: 11208413
    Abstract: The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: December 28, 2021
    Assignee: ALMAG DISCOVERY LIMITED
    Inventors: Peter Hewitt, Frank Burkamp, Andrew Wilkinson, Hugues Miel, Colin O'Dowd
  • Pharmaceutical compounds
    Patent number: 11053213
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 6, 2021
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Peter Hewitt, Mary Melissa McFarland, James Samuel Shane Rountree, Frank Burkamp, Christina Bell, Lauren Proctor, Matthew Duncan Helm, Colin O'Dowd, Timothy Harrison
  • PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
    Publication number: 20210128560
    Abstract: The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.
    Type: Application
    Filed: March 12, 2018
    Publication date: May 6, 2021
    Inventors: Peter HEWITT, Frank BURKAMP, Andrew WILKINSON, Hugues MIEL, Colin O'DOWD
  • 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)
    Publication number: 20210070773
    Abstract: Inhibitors of ubiquitin specific protease 19 (USP19) of Formula (I) are provided, together with pharmaceutical compositions comprising said inhibitors, and methods of use thereof. The compounds can be used in in the treatment of muscular atrophy, obesity, insulin resistance or type II diabetes or in reducing the loss of muscle mass.
    Type: Application
    Filed: January 31, 2019
    Publication date: March 11, 2021
    Inventors: James Samuel Shane ROUNTREE, Steven Kristopher WHITEHEAD, Adam Piotr TREDER, Lauren Emma PROCTOR, Steven David SHEPHERD, Frank BURKAMP, Joana Rita Castro COSTA, Colin O'DOWD, Timothy HARRISON
  • Piperidine derivatives as inhibitors of ubiquitin specific protease 7
    Patent number: 10766903
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 8, 2020
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Colin O'Dowd, Tim Harrison, Peter Hewitt, Shane Rountree, Miel Hugues, Frank Burkamp, Linda Duncan Jordan, Matthew Helm, Fabio Broccatelli, James John Crawford, Lewis Gazzard, Ingrid Wertz, Wendy Lee
  • PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
    Publication number: 20190256518
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 22, 2019
    Inventors: Colin O'DOWD, Tim HARRISON, Peter HEWITT, Shane ROUNTREE, Miel HUGUES, Frank BURKAMP, Linda Duncan JORDAN, Matthew HELM, Fabio BROCCATELLI, James John CRAWFORD, Lewis GAZZARD, Ingrid WERTZ, Wendy LEE
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20190233394
    Abstract: The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
    Type: Application
    Filed: July 26, 2017
    Publication date: August 1, 2019
    Applicant: Almac Discovery Limited
    Inventors: Peter HEWITT, Mary Melissa MCFARLAND, James Samuel Shane ROUNTREE, Frank BURKAMP, Christina BELL, Lauren PROCTOR, Matthew Duncan HELM, Colin O'DOWD, Timothy HARRISON
  • AKT inhibitor compounds for treatment of cancer
    Patent number: 9156853
    Abstract: The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of the serine/threonine kinase, AKT. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: October 13, 2015
    Assignee: ALMAC DISCOVERY LIMITED
    Inventors: Timothy Harrison, Colin O'Dowd, Steven Shepherd, Graham Trevitt, Lixin Zhang, Frank Burkamp
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20150045377
    Abstract: The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of the serine/threonine kinase, AKT. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 12, 2015
    Inventors: Timothy Harrison, Colin O'Dowd, Steven Shepherd, Graham Trevitt, Lixin Zhang, Frank Burkamp
  • Bottle
    Patent number: D688134
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: August 20, 2013
    Assignee: Bruni Glass S.p.A.
    Inventor: Colin O'Dowd